14 Feb 2026
Patient selection for tricuspid TEER in 2026
Anchorperson:
S. Kuwata
Spokesperson:
A. Lee
Summary
This session focuses on optimizing patient selection for tricuspid transcatheter edge-to-edge repair (TEER) in 2026. It integrates anatomical, haemodynamic, and clinical criteria to identify ideal candidates, explores evolving treatment boundaries between TEER, transcatheter tricuspid valve replacement (TTVR), and medical management, and applies evidence from key trials to real-world clinical cases.
Learning Objectives
- To identify optimal candidates for tricuspid TEER in contemporary practice
- To integrate anatomical, haemodynamic, and clinical criteria into patient selection
- To understand the evolving boundaries between TEER, TTVR, and conservative management
- To apply lessons from current evidence (TRILUMINATE Pivotal, TRISCEND-II, CLASP TR, etc.) to real-world cases
